Code of Business Conduct and Ethics
Bluebird bio cuts 30% of its workforce as gene therapy dreams dashed in Europe, delayed in US | Fierce Pharma
BLUE stock on watch as Morgan Stanley predicts regulatory win (NASDAQ:BLUE) | Seeking Alpha
bluebird bio Stock (NASDAQ:BLUE), Quotes and News Summary - Benzinga
bluebird bio Stock (NASDAQ:BLUE), Quotes and News Summary - Benzinga
Stock Down 98% From Peak, Bluebird Bio Could Run Out Of Cash
bluebird bio completes spin-off of cell therapy company 2seventy bio | Seeking Alpha
Eric Hacherl (@EricHacherl) / Twitter
Why Bluebird Bio Stock Is Taking Flight Today | The Motley Fool
Five things for pharma marketers to know: Monday, August 6, 2018 - MM+M - Medical Marketing and Media
Will Bluebird Bio's Big Gamble Payoff? | Biotech Investing | Sick Economics
bluebird bio: Returning To A Previous Winner (NASDAQ:BLUE) | Seeking Alpha
BLUEBIRD BIO, INC. : BLUE Stock Price | US09609G1004 | MarketScreener
Pfizer Is in Talks to Buy Sickle-Cell Drugmaker, WSJ Reports - Bloomberg
Bluebird bio CMO quits amid a roller coaster year and upcoming split | Fierce Biotech
Will Vertex's Sickle Cell Gambit Sink bluebird bio's Stock? | The Motley Fool
Bluebird Bio sees Europe as first market for its gene therapies | Fierce Biotech
bluebird bio Stock (NASDAQ:BLUE), Quotes and News Summary - Benzinga
Gene Editing Stocks To Consider After Bluebird Bio's Breakthroughs
JPM 2022: Bluebird bio hopes for clear skies ahead as it gears up for trio of gene therapy launches | Fierce Pharma
Monday's Top Analyst Upgrades and Downgrades: Applied Materials, BJ's Wholesale, Bluebird Bio, eBay, Foot Locker, Kohl's, Salesforce, Snowflake and More – 24/7 Wall St.
